PTGX Protagonist Therapeutics Inc

Protagonist Therapeutics announced that clinical data on rusfertide, including the Phase 3 VERIFY study for polycythemia vera, will be presented at the 67th Annual American Society of Hematology (ASH) Annual Meeting. Four presentations, encompassing both oral and poster sessions, will detail the durability of response, safety, patient-reported outcomes, and long-term treatment results of rusfertide. The presentations will occur from December 6-9, 2025, in Orlando, Florida.

Protagonist Therapeutics announced that data from its Phase 2b ANTHEM-UC study for icotrokinra in ulcerative colitis will be presented at the United European Gastroenterology Week Berlin 2025. The presentation will detail the week 12 results from the randomized, double-blind, placebo-controlled, treat-through, dose-ranging trial. Icotrokinra is an investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor.

Exchange Traded Concepts LLC has reduced its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 29.2%, selling 13,839 shares, though institutional ownership remains high at 98.63%. Despite missing quarterly EPS and revenue estimates, analysts maintain a "Moderate Buy" rating with an average target price of $85.08, while the stock trades near its 52-week high with a $5.5 billion market cap. Insider selling by a director was also noted, reducing their ownership by 70.05%.

Protagonist Therapeutics announced that clinical data on rusfertide, including results from the Phase 3 VERIFY study for polycythemia vera, will be featured in four presentations at the 67th Annual American Society of Hematology (ASH) Annual Meeting. The presentations will cover durability of response, safety, patient-reported outcomes, observations on dermatologic examinations, and long-term treatment results from the Phase 2 THRIVE extension study. This highlights the company's progress with rusfertide, a lead pipeline candidate.

Assenagon Asset Management S.A. significantly reduced its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 28.4% in the third quarter, selling 26,119 shares and retaining 65,756 shares valued at $4.37 million. This move comes as institutional investors now own about 98.63% of the company's stock, while a director also sold a substantial portion of his shares. The biopharmaceutical company recently missed its quarterly earnings and revenue expectations but maintains a "Moderate Buy" consensus rating from analysts with an average target price of $85.08.

Barclays has increased its target price for Protagonist Therapeutics (PTGX) to $108.00 from $88.00, maintaining an 'Overweight' rating, reflecting continued confidence in the company. This follows a trend of positive analyst outlooks, with other firms also raising price targets and favorable ratings. Despite the positive analyst sentiment, GuruFocus estimates a potential downside based on its GF Value fair value calculation.